Comparative Pharmacology
Head-to-head clinical analysis: TESTIM versus TESTOPEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTIM versus TESTOPEL.
TESTIM vs TESTOPEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to and activates androgen receptors, modulating gene expression leading to male sexual development and maintenance of secondary sexual characteristics.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
Apply 5 g (1 tube) of 1% gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen once daily, preferably in the morning. Dosage may be adjusted to 10 g (2 tubes) depending on clinical response. Apply immediately after opening and avoid bathing or swimming for at least 30 minutes.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
None Documented
None Documented
Terminal elimination half-life of testosterone from serum is approximately 10-100 minutes after intravenous administration, but after transdermal application of Testim, the apparent half-life is longer (around 1-2 hours) due to continued absorption from the skin depot. The half-life of active metabolites (e.g., dihydrotestosterone) is about 2-3 hours.
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Category C
Category C
Androgen
Androgen